Nestlé Health Science and Enterome confirm microbiome deal

The research collaboration aims to advance Enterome’s EB1010, the company’s lead EndoMimics candidate designed to provide improved therapeutic outcomes for patients with these conditions.

The two companies are also committed to identifying and developing a suite of novel AllerMimics (allergen immunotherapies for food allergies) using Enterome’s Mimicry platform.

The initial focus is on peanut allergens as the basis for a new class of immunotherapies that aim to suppress allergic reactions.

“AllerMimics are a truly new class of specific antigens produced by the microbiome that are similar to food allergens and work by helping the body’s immune system tolerate those specific allergens,”​ explains Dr. Christoph Boni, Chief Scientific Officer of Enterome.

“We are excited to partner with Enterome on their unique microbiome drug discovery platform, striving to develop first-in-class, high-quality treatment solutions that will help patients live healthier lives.”​ adds Hans-Jürgen Wörle, Chief Scientific and Medical Officer of Nestlé Health Science.

40 million euros up front in cash

Under the financial terms of the agreement, Enterome will receive up to €40 million in cash and equity from Nestlé Health Science.

The Paris-based firm is also eligible to receive clinical payments and core sales payments for each licensed therapeutic candidate, plus royalties on net sales.

Further terms will have Enterome assume responsibility for lead drug discovery activities and incur related costs until the investigational new drug (IND) application.

Leave a Comment